跳至主要内容
临床试验/NCT05706558
NCT05706558招募中不适用

Retrospective Review of Esophageal Cancer at MSKCC

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2016年12月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
4,000
试验地点
1
主要终点
. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)

研究概览

简要总结

Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
  • Pathologic staged T3 tumors (pT3)

排除标准

  • Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
  • Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
  • Patients undergoing salvage esophagectomy
  • Evidence of distant metastatic disease
  • Patients with a positive proximal or distal margin

研究组 & 干预措施

Circumferential resection margin (CRM)

Participants will have a diagnosis of esophageal carcinoma and residual tumor >1 mm from the CRM

干预措施: Esophagectomy (Procedure)

Circumferential resection margin (CRM)-close

Participants will have a diagnosis of esophageal carcinoma and residual tumor >0-1 mm from the CRM

干预措施: Esophagectomy (Procedure)

Circumferential resection margin (CRM)+

Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM

干预措施: Esophagectomy (Procedure)

结局指标

主要结局

. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)

时间窗: Up to 2 years

Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.

次要结局

  • Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).(Up to 2 years)
  • Overall survival and progression-free survival (measured from date of surgery)(Up to 2 years)
  • Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).(Up to 2 years)
  • Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).(Up to 2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验